10. The CF Foundation recommends that healthcare personnel should not wear artificial fingernails or nail extenders when having direct contact with people with CF (Boyce & Pittet, 2002 [Category IA for high-risk patients]; WHO, 2009 [Category IA for all patients]). 11. The CF Foundation recommends that healthcare personnel should disinfect their stethoscopes before and after use on each patient in accordance with institutional IP&C policies. Stethoscopes that remain in the patient's room and are dedicated for use only for that patient do not need to be disinfected before and after use (Siegel et al., 2006 [Category IB] ). 12. The CF Foundation recommends that healthcare personnel caring for people with CF should not be routinely screened for methicillin-resistant Staphylococcus aureus (MRSA) colonization unless they are epidemiologically linked to a cluster of MRSA infections in accordance with institutional IP&C policies and national guidelines (Siegel et al., 2006 [Category IB] ). Isolation Precautions 13. The CF Foundation recommends that all healthcare personnel implement Contact Precautions (i.e., wear a gown and gloves) when caring for all people with CF regardless of respiratory tract culture results, in ambulatory and inpatient settings [Category IB/IC]). 14. The CF Foundation does not recommend that healthcare personnel wear a mask routinely when caring for people with CF.
However, the CF Foundation recommends mask use per CDC guidelines, as follows: a. Surgical (procedure, isolation) masks are worn by healthcare personnel caring for any patient under Droplet Precautions with suspected or confirmed pathogens that are transmitted by the droplet route (e.g., adenovirus, rhinovirus, influenza virus, or Mycoplasma pneumoniae). b. Masks and eye protection should be worn by healthcare personnel if splashes or sprays of respiratory tract secretions are anticipated as per Standard Precautions. c. N-95 respirators (masks) or powered air-purifying respirators (PAPRs) are worn by healthcare personnel caring for any patient under Airborne Precautions (in an airborne infection isolation room [AIIR] ) for suspected or confirmed infection with Mycobacterium tuberculosis. (Saiman, Siegel, & CF Foundation, 2003 [Category IA] ; Siegel et al., 2007 [Category IB] ; Jensen et al., 2005 [Category IB]) 15. The CF Foundation recommends placing people with CF who are acid-fast bacilli (AFB) smear positive for the first time under Airborne Precautions (AIIR requirements: negative-pressure single room, more than 12 air exchanges per hour, air exhausted to the outside) in ambulatory and inpatient settings until M. tuberculosis infection has been excluded. Alternatively, in geographic locations with a very low incidence of TB, a risk assessment that includes the likelihood of exposure to individuals with tuberculosis (TB) (e.g., travel or visitors from high-prevalence areas) may be used to guide the use of AIIRs. Consult with institutional IP&C staff and/or infectious disease physicians (Saiman, Siegel, & CF Foundation, 2003 [Category IA] ; Jensen et al., 2005; [Category IA/IC]). 16. The CF Foundation concludes that there is insufficient evidence at the time of publication of this document for or against placing people with CF who are infected with nontuberculous Mycobacteria (NTM) under Airborne Precautions (Certainty: low). Practices by People with CF and Family Members/Friends 17. The CF Foundation recommends that all people with CF, regardless of their respiratory tract culture results, be separated by at least 6 feet (2 meters) from other people with CF in all settings, to reduce the risk of droplet transmission of CF pathogens. This does not apply to members of the same household. 18. The CF Foundation recommends that all people with CF and their family members/friends perform hand hygiene (with either alcoholbased hand rub or antimicrobial soap and water) when there is potential for contamination of hands with pathogens, such as the following: a. Entering and exiting CF clinics, clinic exam rooms, or hospital rooms b. Hands become contaminated with respiratory secretions (e.g., after coughing or performing PFTs or chest physiotherapy) (Saiman, Siegel, & CF Foundation, 2003 [Category IA]) 19. The CF Foundation does not recommend that people with CF wear gowns or gloves in CF clinics, in other ambulatory healthcare settings, or while hospitalized. 20. The CF Foundation recommends that people with CF be instructed to follow Respiratory Hygiene practices to contain their secretions when coughing or sneezing (i.e., cough into a tissue, immediately discard soiled tissue into a trash receptacle, and perform hand hygiene after disposing of soiled tissues). A covered trash receptacle with a foot pedal is preferred. (Saiman, Siegel, & CF Foundation, 2003 [Category II]; Siegel et al., 2007 [Category IB] ). 21. The CF Foundation recommends that all people with CF wear a surgical (procedure, isolation) mask when in a healthcare facility to reduce the risk of transmission or acquisition of CF pathogens. Masks should be worn throughout the facility, including in restrooms. Masks should not be worn during pulmonary function testing, in the clinic exam room, or in the patient's hospital room. If the optimal size mask is not available (e.g., for small infants), use the smallest mask available. If a mask is not tolerated by an individual with CF who is having respiratory distress, encourage that person to follow Respiratory Hygiene practices. Masks should be changed when wet (Siegel et al., 2007 [Category IB] 23. The CF Foundation recommends that a. Tap water or well water that meets local public health standards, distilled water, or bottled water may be used by people with CF i. For drinking ii. For bathing iii. For cleaning nebulizers and other respiratory equipment (e.g., airway clearance devices, spacers, and neti pots) if followed by disinfection iv. For the water needed for heat disinfection (e.g., boiling, microwaving, and steam sterilizing) b. Only sterile water be used for nasal rinses (e.g., neti pots), filling of humidifier reservoirs, and as a final rinse of respiratory equipment (e.g., after cold disinfection) Immunizations/Influenza Chemoprophylaxis 24. The CF Foundation recommends that, as per CDC/Advisory Committee on Immunization Practices (ACIP) recommendations, all healthcare personnel (unless there is a medical contraindication to immunization) should be immunized or have evidence of immunity to mumps, measles, rubella, varicella, pertussis (Tdap), and hepatitis B and receive an annual influenza immunization (CDC, "Prevention," 2013; "Immunization," 2013). 25. The CF Foundation recommends that, as per CDC/ACIP recommendations, all people with CF and their family members/close contacts receive recommended vaccines at the recommended schedule, age, dose, and route of administration unless there is a medical contraindication (CDC, "Prevention," 2013; CDC, "Immunization," 2013) 26. The CF Foundation recommends use of antiviral chemoprophylaxis or treatment (e.g., oseltamivir) for prevention or treatment of influenza according to ACIP recommendations (Saiman, Siegel, & CF Foundation, 2003 [Category IA] ; CDC, "Influenza," 2013). Research Settings 27. The CF Foundation recommends that for all research activities, people with CF, their family members/friends, and healthcare personnel follow relevant IP&C recommendations for that healthcare setting.
II. Recommendations for Microbiology and Molecular Epidemiology
In addition to the microbiology recommendations for processing CF respiratory specimens described in the 2003 Infection Control Guideline for CF (Saiman, Siegel, & CF Foundation, 2003) , the CF Foundation recommends implementation of the following recommendations:
Review Center-Specific Microbiology Data 28. The CF Foundation recommends that all CF centers obtain and review center-specific quarterly surveillance reports (e.g., data from the local clinical microbiology laboratory or the CF Foundation Patient Registry) of the incidence and prevalence of respiratory tract pathogens at their centers. This review should be conducted in collaboration with institutional IP&C teams and microbiology laboratory directors (Saiman, Siegel, & CF Foundation, 2003 In the absence of clinical features suggestive of NTM pulmonary disease, individuals who are not capable of spontaneously producing sputum do not require screening cultures for NTM. The CF Foundation and ECFS recommend against the use of oropharyngeal swabs for NTM screening (Leung & Oliver, 2013) .
33. The CF Foundation concludes that there is insufficient evidence at the time of publication of this document to recommend criteria by which to consider a person with CF who previously had Burkholderia species isolated from respiratory tract cultures to be Burkholderia-free [Certainty: low].
III. Recommendations for CF Clinics and Other Ambulatory Care Settings
In addition to the core recommendations, the CF Foundation recommends implementing the following recommendations in CF clinics and other ambulatory care areas, including those clinics where people with CF who have undergone lung or liver transplantation are followed.
Scheduling in CF Clinics 34. The CF Foundation recommends that CF clinics schedule and manage people with CF in ways to minimize time in common waiting areas. Such strategies include the following: a. Stagger clinic schedule b. Place people with CF regardless of their respiratory culture results in an exam room immediately on arrival to the clinic c. Use a pager system or personal cell phone to alert people with CF that an exam room is available d. Keep a person with CF in one exam room while the CF care team rotates through the exam room e. Do not share common items (e.g., clinic computer and toys), and request that people with CF bring their own recreational items to clinic appointments (Saiman, Siegel, & CF Foundation, 2003 [Category II]) 35. The CF Foundation recommends that infants under 2 years of age be separated from other people with CF in CF clinics until adequate infection control education has been provided to and is understood by the caregivers. See the Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis (Certainty: low). 36. The CF Foundation recommends that all newly diagnosed people with CF be separated from other people with CF in CF clinics until adequate IP&C education has been provided to and is understood by newly diagnosed individuals and their caregivers. 37. The CF Foundation concludes that there is insufficient evidence at the time of publication of this document for or against routinely scheduling CF clinics on the basis of specific pathogens isolated from respiratory tract cultures (Certainty: low). Pulmonary Function Testing 38. The CF Foundation recommends that PFTs be performed in one of the following ways: a. In the exam room at the beginning of the clinic visit b. In a negative-pressure room (AIIR) c. In a PFT laboratory with either portable or integrated high-efficiency particulate (HEPA) filters d. In a PFT laboratory without HEPA filtration, allowing 30 minutes to elapse before the next person with CF enters the PFT laboratory Environmental Practices 39. The CF Foundation recommends that exam rooms be cleaned and disinfected between patients using a 1-step process and Environmental Protection Agency (EPA)-registered hospital-grade disinfectant/detergent designed for housekeeping in accordance with institutional IP&C policies (Saiman, Siegel, & CF Foundation, 2003 [Category IB] Room Placement 41. The CF Foundation recommends that people with CF be placed in a single-patient room. Only people with CF who live in the same household may share a hospital room (Saiman, Siegel, & CF Foundation, 2003 [Category II]; Siegel et al., 2006 [Category IB] ). 42. The CF Foundation recommends placing people with CF who are solid-organ transplant recipients in a single patient room in accordance with institutional policy and national guidelines. There is insufficient evidence to recommend for or against Protective Environment (i.e., positive pressure room and HEPA filtration) for solid-organ recipients (Saiman, Siegel, & CF Foundation, 2003 [Category II]; Siegel et al., 2007 [No recommendation, unresolved issue] In addition to the core recommendations, the CF Foundation recommends implementing the following recommendations in nonhealthcare settings.
Families with More than 1 Person with CF 50. The CF Foundation recommends that it is preferable that people with CF who live in the same household perform airway clearance with only 1 person with CF in the room during treatment (Saiman, Siegel, & CF Foundation, 2003 [Category II] ). Events and Activities 51. The CF Foundation recommends against CF-specific camps or CF-specific educational retreats for groups of people with CF. Only 1 individual with CF should attend any camp or educational retreat unless they live in the same household. However, family members who do not have CF may attend educational retreats. People with CF are encouraged to participate in camps and sports with non-CF individuals (Saiman, Siegel, & CF Foundation, 2003 Category IB). 52. People with CF and their parents or legal guardians are not obligated to disclose the diagnosis of CF or the results of respiratory tract cultures to school or day care personnel. However, the CF Foundation recommends disclosure so that school or day care personnel can be made aware of the importance of IP&C principles and practices for the protection of students with CF and can make the recommended accommodations. Such information must be maintained as confidential medical information unless the person with CF and/or parent or legal guardian choose to make this information known (Saiman, Siegel, & CF Foundation, 2003, Category II) . 53. The CF Foundation recommends that people with CF attending the same day care and/or school should not be in the same room at the same time unless they live in the same household. The CF Foundation recommends education of day care/school personnel on the principles of IP&C for CF so they can work with people with CF and/or parents or legal guardians to develop strategies to minimize contact between people with CF (e.g., assignment to separate classrooms and separation during other scheduled common activities, including lunch, physical education, and recess) (Saiman, Siegel, & CF Foundation, 2003 [Category II]). 54. The CF Foundation recommends that only 1 person with CF attend CF Foundation-sponsored, healthcare-sponsored, or CF center-sponsored indoor events (e.g., CF Education Days) unless they live in the same household, to reduce the risk of person-toperson transmission of CF pathogens. 55. The CF Foundation recommends developing and utilizing alternative CF education programs, (e.g., videotapes, video conferencing, CD-ROM web-based learning, and apps) that do not require face-to-face meetings among people with CF (Saiman, Siegel, & CF Foundation, 2003 [Category II]). 56. The CF Foundation recommends that people with CF can attend CF Foundation-sponsored, healthcare-sponsored, or CF centersponsored outdoor events (e.g., Great Strides) providing they maintain a distance of at least 6 feet (2 meters) from others with CF. MRSA 57. The CF Foundation recommends that people with CF should avoid direct contact with people with skin and soft tissue infections caused by MRSA unless wounds are covered, hand hygiene is performed frequently, personal items (e.g., towels) are not shared, sports equipment is cleaned between use, and cleaning protocols for environmental surfaces are established to reduce the risk of MRSA transmission (CDC, "MRSA," 2010). 58. The CF Foundation recommends that people with CF and respiratory cultures positive for MRSA should not be restricted from contact with people without CF in congregate settings (e.g., sports teams, classrooms, and the workplace) if the person with CF performs appropriate hand and respiratory hygiene (CDC, "MRSA," 2010). Nebulizers: Cleaning and Disinfecting 59. The CF Foundation recommends that the following steps be performed for nebulizers used in the home as soon as possible after each use: a. Clean the nebulizer parts with dish detergent soap and water b. Disinfect the nebulizer parts using one of the following methods. Heat Methods a. Place in boiling water and boil for 5 minutes b. Place in a microwave-safe receptacle submerged in water and microwave for 5 minutes c. Use a dishwasher if the water is more than or equal to 70°C or 158°F for 30 minutes. d. Use an electric steam sterilizer Cold Methods a. Soak in 70% isopropyl alcohol for 5 minutes b. Soak in 3% hydrogen peroxide for 30 minutes i. Rinse off the cold-method disinfectant using sterile water, not tap water; the final rinse must be with sterile or filtered (less than or equal to 0.2-micron filter) water ii. Air dry the nebulizer parts before storage (Saiman, Siegel, & CF Foundation, 2003 [Category II]) 60. The CF Foundation recommends that nebulizers used in the home should not be disinfected with acetic acid (vinegar), bleach solutions, or benzalkonium chloride (e.g., "Control III"). Leisure Activities 61. The CF Foundation recommends that people with CF should limit prolonged and/or repeated exposure to activities that generate dust from soil and organic matter (e.g., gardening and lawn mowing) to decrease exposure to potential soilborne pathogens (e.g., Burkholderia spp. and Aspergillus spp.). 62. The CF Foundation recommends that people with CF should avoid exposure to construction and renovation activities that generate dust to decrease exposure to potential pathogens (e.g., Aspergillus spp.). 63. The CF Foundation recommends that people with CF can swim in pools or water parks with adequate disinfection (e.g., chlorination). 64. The CF Foundation recommends that people with CF avoid activities in hot tubs, whirlpool spas, and stagnant water. 65. There is insufficient evidence at the time of publication of this document for the CF Foundation to recommend for or against people with CF avoiding activities in natural bodies of water that are not stagnant (e.g., ocean, ponds, and hot springs) [Certainty: low]. Contact with Pets or Farm Animals 66. The CF Foundation recommends that people with CF perform hand hygiene after changing the litter, handling feces, cleaning and disinfecting the cages or fish tanks of their pets, or interacting with farm animals (CDC, "Healthy pets," 2013). 67. The CF Foundation recommends that people with CF avoid cleaning stalls, pens, or coops.
VI. Recommendations for Healthcare Personnel with CF
In addition to the core recommendations, the CF Foundation recommends implementing the following recommendations for healthcare personnel with CF.
68. The CF Foundation recommends that healthcare personnel with CF should not provide care for other people with CF. 69. The CF Foundation recommends that people with CF interested in a career in healthcare receive counseling from their CF care team regarding specialty areas wherein job duties minimize the risk of transmission or acquisition of potential pathogens (Saiman, Siegel, & CF Foundation, 2003 [Category II] ). 70. The CF Foundation recommends that healthcare personnel with CF consider informing their employers' workforce health and safety department about their diagnosis of CF to ensure that job duties are assigned and care practices are adopted that minimize the risk of acquisition or transmission of potential pathogens. This disclosure is legally required to be kept confidential. 71. The CF Foundation recommends that when it is known that a healthcare provider with or without CF is infected/colonized with MRSA, work assignments should be made according to local hospital policy (Saiman, Siegel, & CF Foundation, 2003 [Category II] ). 72. The CF Foundation recommends that healthcare personnel with CF be assigned to care for patients without CF on a case-by-case basis, considering health-and behavior-related factors, such as a. Frequency and severity of coughing episodes, quantity of sputum production during these episodes, and ability to contain respiratory tract secretions b. Ability to use barrier precautions and adhere to IP&C guidelines, Centers for Medicare & Medicaid Services, Healthcare Infection Control Practices Advisory Committee (HICPAC), and CDC guidelines c. Risk of transmission of pathogens by healthcare personnel with CF in the context of specific job duties. (Saiman, Siegel, & CF Foundation, 2003 [Category II]) VII. Recommendations for Psychosocial and Medical Impact of IP&C The CF Foundation recommends implementing the following recommendations to reduce the psychosocial impact of IP&C for people with CF, their families, and healthcare personnel.
73. The CF Foundation recommends educating, when appropriate, friends, teachers, employers, and coworkers about the rationale for the IP&C recommendations (Saiman, Siegel, & CF Foundation, 2003 [Category II]). 74. The CF Foundation recommends identifying CF center-specific concerns for the potential psychosocial impact of the IP&C guideline for people with CF in the hospital, clinic, community, school, and home and strategies, including an available counselor, to minimize the negative impact (Saiman, Siegel, & CF Foundation, 2003 [Category II] ). 75. The CF Foundation recommends that the CF care team inform people with CF and their parents or legal guardians of their microbiologic status. People with CF and their parents or legal guardians will then determine whom they will inform (Saiman, Siegel, & CF Foundation, 2003 [Category II] ). 76. The CF Foundation recommends collaboration with the child life staff to ensure individualized programs consistent with the recommended IP&C guidelines (Saiman, Siegel, & CF Foundation, 2003 [Category II] ). 77. The CF Foundation recommends making accommodations (e.g., providing entertainment, enhancing communication with the outside world, facilitating visits with non-CF individuals, and adapting child life programs) to relieve the psychosocial stress of inpatient and outpatient IP&C guidelines without placing people with CF at risk for transmission or acquisition of pathogens (Saiman, Siegel, & CF Foundation, 2003 [Category II]).
Definitions:
Grading Systems Used in the Updated IP&C Guidelines for CF, 2013
Source of Recommendation Grading Strategy
Comments For the systematic review, searches of PubMed, EMBASE, and the Cochrane Central Register of Controlled Studies were conducted by the Johns Hopkins University research team in June 2012. Searches of reference lists for all eligible articles and Cochrane reviews were also completed. Committee members provided additional potentially eligible studies. Studies performed in the cystic fibrosis (CF) population were sought preferentially, but studies conducted in other populations considered relevant were also reviewed. Two independent reviewers screened search results for eligible studies. Details about eligible studies were abstracted and a report, including evidence tables and qualitative synthesis, was submitted to the CF Foundation and disseminated to the committee.
Additionally, the Johns Hopkins University research team identified relevant guidelines and Cochrane reviews through searches (completed in August 2012) of the National Guideline Clearinghouse, United Kingdom CF Trust website, CF Foundation guidelines database, the Cochrane Library, and lists provided by the committee chairs. Details from these sources, including recommendation statements, were abstracted and provided to the committee.
Number of Source Documents
The evidence review identified a total of 2,031 unique citations. 1,857 citations were excluded during abstract screening. During full-text screening (n=174) a further 121 citations were excluded, 35 were flagged as background, and the full-text for 3 citations was unable to be retrieved, leaving 15 studies (published in 16 articles) as eligible for inclusion in the evidence review (see the "Availability of Companion Documents" field). , and the Advisory Committee on Immunization Practices (ACIP) were also included, and their grade of evidence was retained without a vote by the committee (see Table 3 in the original guideline document). New recommendations that had not been published previously were developed by the committee. Inclusion of the recommendations was determined by anonymous voting. At least 80% approval by the committee members (i.e., consensus) was set as the threshold for acceptance of new recommendations, relevant recommendations from the 2003 Infection Control Guideline for CF, or relevant recommendations from other guidelines developed for non-CF populations.
Methods
The CDC/HICPAC guidelines and the WHO hand hygiene guideline cited in this document used a unique HICPAC grading system that was used for HICPAC guidelines published before 2009. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was adopted for use by CDC/HICPAC/ACIP in 2009 and is used by more than 70 organizations worldwide. However, the GRADE system can result in Infection Prevention and Control (IP&C) guidelines that are more likely to include expert consensus compared with guidelines developed for specific treatment regimens that have randomized clinical trials as their evidence base. Limitations of the GRADE system that may impact developing IP&C guidelines include (1) questions for which little or no evidence is available on which to base a recommendation, (2) little or no requirement for evidence given the high probability of a recommendation's success, and (3) difficulty assessing the strength of evidence from studies performed in varying populations with varying study designs. The evidence base for this updated guideline had similar limitations; thus, the recommendations in this guideline are often based on expert consensus. 
Cost Analysis
The guideline developers reviewed published cost analyses.
Method of Guideline Validation
External Peer Review
Internal Peer Review
Description of Method of Guideline Validation External Review
In May 2013, the Cystic Fibrosis (CF) Foundation made a draft of the updated guideline available for comment to the CF community, including the teams at CF care centers and people with CF. Infection preventionists and healthcare epidemiologists were also notified of the availability of the document for comment. All comments were considered by the committee, and the recommendations and background information were revised as appropriate. This guideline was reviewed and endorsed by The Society for Healthcare Epidemiology of America (SHEA) and by the Association for Professionals in Infection Control (APIC).
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